SULFINPYRAZONE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for sulfinpyrazone and what is the scope of freedom to operate?
Sulfinpyrazone
is the generic ingredient in two branded drugs marketed by Novartis, Barr, Ivax Pharms, Par Pharm, Vangard, and Watson Labs, and is included in nine NDAs. Additional information is available in the individual branded drug profile pages.There are four drug master file entries for sulfinpyrazone.
Summary for SULFINPYRAZONE
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 6 |
NDAs: | 9 |
Drug Master File Entries: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 99 |
Clinical Trials: | 3 |
Patent Applications: | 6,877 |
DailyMed Link: | SULFINPYRAZONE at DailyMed |
Recent Clinical Trials for SULFINPYRAZONE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Federal University of São Paulo | Phase 4 |
Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 |
China Medical University Hospital | Phase 2 |
Medical Subject Heading (MeSH) Categories for SULFINPYRAZONE
Anatomical Therapeutic Chemical (ATC) Classes for SULFINPYRAZONE
US Patents and Regulatory Information for SULFINPYRAZONE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Barr | SULFINPYRAZONE | sulfinpyrazone | TABLET;ORAL | 087665-001 | Sep 17, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Novartis | ANTURANE | sulfinpyrazone | TABLET;ORAL | 011556-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Watson Labs | SULFINPYRAZONE | sulfinpyrazone | TABLET;ORAL | 087667-001 | May 26, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |